Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 23;13(7):2146.
doi: 10.3390/nu13072146.

New Insights into Non-Dietary Treatment in Celiac Disease: Emerging Therapeutic Options

Verónica Segura  1 , Ángela Ruiz-Carnicer  1 , Carolina Sousa  1 , María de Lourdes Moreno  1
Affiliations
Review

New Insights into Non-Dietary Treatment in Celiac Disease: Emerging Therapeutic Options

Verónica Segura et al. Nutrients. .

Abstract

To date, the only treatment for celiac disease (CD) consists of a strict lifelong gluten-free diet (GFD), which has numerous limitations in patients with CD. For this reason, dietary transgressions are frequent, implying intestinal damage and possible long-term complications. There is an unquestionable need for non-dietary alternatives to avoid damage by involuntary contamination or voluntary dietary transgressions. In recent years, different therapies and treatments for CD have been developed and studied based on the degradation of gluten in the intestinal lumen, regulation of the immune response, modulation of intestinal permeability, and induction of immunological tolerance. In this review, therapeutic lines for CD are evaluated with special emphasis on phase III and II clinical trials, some of which have promising results.

Keywords: celiac disease; gliadin; gluten; gluten immunogenic peptides; gluten-free diet; non-dietary therapies.

PubMed Disclaimer

Conflict of interest statement

The authors have no potential conflict of interest to declare. None of the authors have any conflicts of interest that could affect the performance of the work or the interpretation of the data.

Figures

Figure 1
Figure 1
Studies reporting gluten exposure rates in CD patients on a supposed GFD. CD, celiac disease; GFD, gluten-free diet [23,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58].
Figure 2
Figure 2
Emerging therapeutic approaches for non-dietary CD treatment. APC, antigen-presenting cell; CD, celiac disease; IL-15, interleukin 15; TNF, tumor necrosis factor; tTG, tissue transglutaminase.
Figure 3
Figure 3
Clinical and preclinical development pipeline for CD. CD, celiac disease; PEP, prolyl endopeptidases; TNF, tumor necrosis factor; tTG, tissue transglutaminase.
See this image and copyright information in PMC

References

    1. Lebwohl B., Cao Y., Zong G., Hu F.B., Green P.H.R., Neugut A.I., Rimm E.B., Sampson L., Dougherty L.W., Giovannucci E., et al. Long-term gluten consumption in adults without celiac disease and risk of coronary heart disease: Prospective cohort study. BMJ. 2017;357:j1892. doi: 10.1136/bmj.j1892. - DOI - PMC - PubMed
    1. Al-Toma A., Volta U., Auricchio R., Castillejo G., Sanders D.S., Cellier C., Mulder C.J., Lundin K.E.A. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. United Eur. Gastroenterol. J. 2019;7:583–613. doi: 10.1177/2050640619844125. - DOI - PMC - PubMed
    1. Lebwohl B., Sanders D.S., Green P.H.R. Coeliac disease. Lancet. 2018;391:70–81. doi: 10.1016/S0140-6736(17)31796-8. - DOI - PubMed
    1. Ludvigsson J.F., Murray J.A. Epidemiology of celiac disease. Gastroenterol. Clin. N. Am. 2019;48:1–18. doi: 10.1016/j.gtc.2018.09.004. - DOI - PubMed
    1. Singh P., Arora A., Strand T.A., Leffler D.A., Catassi C., Green P.H., Kelly C.P., Ahuja V., Makharia G.K. Global prevalence of celiac disease: Systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 2018;16:823–836.e2. doi: 10.1016/j.cgh.2017.06.037. - DOI - PubMed